Deramiocel improves arm function and cardiac measures in phase 3 trial as FDA advisory panel reviews Capricor's application
Phase 3 trial of deramiocel (CAP-1002) showed significant benefits on upper-limb function and cardiac measures; FDA advisory panel is reviewing the data.